Molecular mechanisms of protease Nexin-1 on regulating tumorgenesis

Abstract

Abstract:Protease nexin-1 (PN-1) is one of the most important members of Serpin superfamily. The abnormal expressions are observed in many human cancers, such as pancreatic cancer, breast cancer, colon cancer, testicular cancer and so on. PN1 participates in tumor cell proliferation, differentiation, apoptosis, angiogenesis and invasion by inhibiting multiple proteases and extracellular signal regulated kinase (ERK) pathways and promotes tumor occurrence, development and metastasis. In prostate cancer particularly, PN1 inhibits tumor occurrence, development and metastasis by inhibiting urokinase plasminogen activator (uPA), Hh signaling pathway and interacting with matrix metalloproteinase (MMP)-9.

Key words:Apoptosis,Neoplasm metastasis,Neoplasm invasiveness,Protease nexin-1

Xin Xiangke, Xu Danmei. Molecular mechanisms of protease Nexin-1 on regulating tumorgenesis[J]. Journal of International Oncology, 2014, 41(2): 81-84.

References

［1］ Boulaftali Y, Adam F, Venisse L, et al. Anticoagulant and antithrombotic properties of platelet protease nexin1［J］. Blood, 2010, 115(1): 97106. ［2］ Bouton MC, Boulaftali Y, Richard B, et al. Emerging role of serpinE2/protease nexin1 in hemostasis and vascular biology［J］. Blood, 2012, 119(11): 24522457. ［3］ Boulaftali Y, Francois D, Venisse L, et al. Endothelial protease nexin1 is a novel regulator of A disintegrin and metalloproteinase 17 maturation and endothelial protein C receptor shedding via furin inhibition［J］. Arterioscler Thromb Vasc Biol, 2013, 33(7): 16471654. ［4］ Boulaftali Y, HoTinNoe B, Pena A, et al. Platelet protease nexin1, a serpin that strongly influences fibrinolysis and thrombolysis［J］. Circulation, 2011, 123(12): 13261334. ［5］ Bergeron S, Lemieux E, Durand V, et al. The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis［J］. Mol Cancer, 2010, 9: 271. ［6］ Binder BR, Mihaly J. The plasminogen activator inhibitor "paradox" in cancer［J］. Immunol Lett, 2008, 118(2): 116124. ［7］ Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI1 paradox in cancer: more than meets the eye［J］. Semin Thromb Hemost, 2013, 39(4): 382391. ［8］ Iacoviello L, Agnoli C, De Curtis A, et al. Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study［J］. BMJ Open, 2013, 3(11): e003725. ［9］ Kim ER, Yang MH, Lim YJ, et al. Association between plasma levels of plasminogen activator inhibitor1 and colorectal neoplasms［J］. Gut Liver, 2013, 7(5): 519523. ［10］ Debucquoy A, Haustermans K, Daemen A, et al. Molecular response to cetuximab and efficacy of preoperative cetuximabbased chemoradiation in rectal cancer［J］. J Clin Oncol, 2009, 27(17): 27512757. ［11］ SelzerPlon J, Bornholdt J, Friis S, et al. Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis［J］. BMC Cancer, 2009, 9: 201. ［12］ Gao S, Krogdahl A, Sorensen JA, et al. Overexpression of protease nexin1 mRNA and protein in oral squamous cell carcinomas［J］. Oral Oncol, 2008, 44(3): 309313. ［13］ Nagahara A, Nakayama M, Oka D, et al. SERPINE2 is a possible candidate promotor for lymph node metastasis in testicular cancer［J］. Biochem Biophys Res Commun, 2010, 391(4): 16411646. ［14］ Fayard B, Bianchi F, Dey J, et al. The serine protease inhibitor protease nexin1 controls mammary cancer metastasis through LRP1mediated MMP9 expression［J］. Cancer Res, 2009, 69(14): 56905698. ［15］ Bianchini G, Qi Y, Alvarez RH, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptorpositive and negative cancers［J］. J Clin Oncol, 2010, 28(28): 43164323. ［16］ McKee CM, Xu D, Cao Y, et al. Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma［J］. J Clin Invest, 2012, 122(11): 40254036. ［17］ McKee CM, Xu D, Muschel RJ. Protease nexin 1: a novel regulator of prostate cancer cell growth and neoangiogenesis［J］. Oncotarget, 2013, 4(1): 12. ［18］ Balsara RD, Ploplis VA. Plasminogen activator inhibitor1: the doubleedged sword in apoptosis［J］. Thromb Haemost, 2008, 100(6): 1029 1036. ［19］ Selbonne S, Azibani F, Iatmanen S, et al. In vitro and in vivo antiangiogenic properties of the serpin protease nexin1［J］. Mol Cell Biol, 2012, 32(8): 14961505. ［20］ Xu D, Suenaga N, Edelmann MJ, et al. Novel MMP9 substrates in cancer cells revealed by a labelfree quantitative proteomics approach［J］. Mol Cell Proteomics, 2008, 7(11): 22152228. ［21］ Xu D, McKee CM, Cao Y, et al. Matrix metalloproteinase9 regulates tumor cell invasion through cleavage of protease nexin1［J］. Cancer Res, 2010, 70(17): 69886998. ［22］ Zheng D, Chen H, Davids J, et al. Serpins for diagnosis and therapy in cancer［J］. Cardiovasc Hematol Disord Drug Targets, 2013, 13(2): 123132.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan.Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells[J]. Journal of International Oncology, 2024, 51(3): 129-136.
[3]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Zhang Keping, Zhao Yongsheng, Yang Juan, Fu Maoyong.Chlorogenic acid induces mitochondrial dysfunction in lung cancer A549 cells by inhibiting the PI3K-Akt pathway[J]. Journal of International Oncology, 2024, 51(1): 21-28.
[6]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[7]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[8]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[9]	Wu Jiali, Zhang Jiahui, Zhang Ping, Xiao Xinyue, Li Rui, Zhang Hongyu.Mechanism of Bcl-2 BH4 selective inhibitor BDA-366 on NK/T cell lymphoma cells[J]. Journal of International Oncology, 2023, 50(7): 413-418.
[10]	Yang Ya, Wang Huili, Liu Yan, Guo Jinfeng, Wang Chunxia, Lyu Min, Shan Changping.Effects of GCSH gene on proliferation and apoptosis of gastric cancer SNU-1 cells[J]. Journal of International Oncology, 2023, 50(5): 257-262.
[11]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[12]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin.Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(2): 117-121.
[13]	Zhu Yi, Chen Jian.Mechanism of hydrogen sulfide in tumorigenesis and development and its donor-mediated anti-tumor effects[J]. Journal of International Oncology, 2023, 50(12): 729-733.
[14]	Zhao Jianhao, Duan Yanchao.Research progress in the pathogenesis of extramedullary disease in multiple myeloma[J]. Journal of International Oncology, 2023, 50(1): 55-59.
[15]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou.Advances in immunotherapy for recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 517-520.